Results 141 to 150 of about 52,475 (270)

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study

, 2022
Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Michiya Tachiiri, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki   +11 more
openalex   +1 more source

Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan

The Journal of Clinical Pharmacology, Volume 65, Issue 12, Page 1889-1899, December 2025.
Abstract In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a
Akinori Nakashima, Akihide Tsujimoto, Masako Saito, Jun Takeda, Makiko Natori, Satoshi Shoji   +5 more
wiley   +1 more source

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding [PDF]

, 2023
Kimberly Snow Caroti, Cecilia Becattini, Marc Carrier, Alexander T. Cohen, Anders Ekbom, Alok A. Khorana, Agnes Lee, Christopher Brescia, Khaled Abdelgawwad, George Psaroudakis, Marcela Rivera, Bernhard Schaefer, Gunnar Brobert, Craig I Coleman   +13 more
openalex   +1 more source

Assessing the link between rivaroxaban concentration and the onset of renal impairment in elderly patients: A retrospective observational study

Asian Journal of Medical Sciences
Background: Rivaroxaban is a widely used anticoagulant, but its impact on renal function, particularly at varying plasma concentrations, remains a critical area of investigation.
Motakatla Usha Rani , Chitra Karuppiah , Penupothu Sree Nagamani   +2 more
doaj   +1 more source

Reduced Left Atrial Appendage Flow Velocity as a Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation

Journal of Arrhythmia, Volume 41, Issue 6, December 2025.
Reduced preprocedural LAAFV is associated with adverse long‐term clinical outcomes after AF ablation, including a significantly increased risk of thromboembolic events. ABSTRACT Background Reduced left atrial appendage flow velocity (LAAFV) on transesophageal echocardiography (TEE) is recognized as a predictor of thromboembolic events (TEs) in patients
Shintaro Yamagami, Satoshi Shizuta, Munekazu Tanaka, Shushi Nishiwaki, Takanori Aizawa, Akihiro Komasa, Takashi Yoshizawa, Tetsuma Kawaji, Chihiro Ota, Naoaki Onishi, Yasuhiro Sasaki, Mitsuhiko Yahata, Kentaro Nakai, Mamoru Hayano, Tetsushi Nakao, Koji Hanazawa, Koji Goto, Takahiro Doi, Toshihiro Tamura, Koh Ono, Takeshi Kimura   +20 more
wiley   +1 more source

Oral Anticoagulant Therapy of Patients With Atrial Fibrillation in Cardiology, Internal Medicine, and Surgery: Temporal Trend

MedComm, Volume 6, Issue 12, December 2025.
The multicenter retrospective study reviewed electronic medical records of 70,187 AF patients from 20 hospitals between January 2015 and December 2023. The main findings were that OAC usage was significant increase particularly in cardiology (29.8% pre‐2018 to 68.8% in 2021–2023), while still below 50% in non‐cardiology departments; influent factors ...
Mingjie Lin, He Huang, Juntao Wang, Hui Sun, Xingsheng Xu, Yan Zhang, Wenqiang Han, Min Chen, Kui Dong, Yingcui Wang, Beian You, Guihua Yao, Jingquan Zhong, Congxin Huang   +13 more
wiley   +1 more source

A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk [PDF]

, 2022
Penghui Liu, Zehua Liu, Ming-Hui Niu, Ping Chen, Yuan-Bin Shi, Fei He, Rong Guo   +6 more
openalex   +1 more source

High‐Throughput Screening Using the Self‐Controlled Tree‐Based Scan Statistic to Identify Medications Associated With Hospitalization for Severe Acute Liver Injury

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 12, December 2025.
ABSTRACT Background Medications associated with acute liver injury (ALI) are primarily identified by case reports. High‐throughput screening of real‐world data could be leveraged to detect hepatotoxicity signals. Objective To apply tree‐based scan statistics in real‐world data to identify drugs associated with hospitalization for severe ALI among ...
Vincent Lo Re III, Craig W. Newcomb, Dean M. Carbonari, Charles E. Leonard, Christopher T. Rentsch, Judith C. Maro   +5 more
wiley   +1 more source

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up

Medicina
Background and Objectives: Rivaroxaban is a direct-acting anticoagulant used to prevent stroke in patients with atrial fibrillation. Rivaroxaban is a substrate for P-glycoprotein, which is encoded by the ABCB1 gene. Rivaroxaban is also metabolized by the
Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahmad   +4 more
doaj   +1 more source

Management and outcome of a dog with hepatic arteriovenous malformation and extensive thrombosis of splanchnic vessels

Veterinary Record Case Reports, Volume 13, Issue 4, December 2025.
Abstract This report describes the diagnosis, treatment and long‐term follow‐up of a dog with hepatic arteriovenous malformation and extensive thrombus of the splanchnic vessels. A 1‐year‐old, male, neutered golden retriever presented with haematochezia and ascites.
Yuqing Sun, Alexa Bersenas, Brigitte A. Brisson   +2 more
wiley   +1 more source